JKN24011

Phase 2Biologic

JJoincare Pharmaceutical Group Industry Co., Ltd

JKN24011 is one of 9 biologic programs targeting Phase 2. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase 2Active, not recruiting

Phase 2Phase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Phase 2

#DrugCompanyPhaseTrials

Suboxone

IIndivior Inc.

Approved

1 2

Vizimpro

Pfizer

Phase 2

1 3

P1101

PPharmaEssentia Japan K.K.

Phase 3

1 4

ABSK061

AAbbisko Therapeutics Co, Ltd

Phase 2

1 5

ABSK-011

AAbbisko Therapeutics Co, Ltd

Phase 2

1 6

Taletrectinib

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 7

TRS005

ZZhejiang Teruisi Pharmaceutical Inc.

Phase 2

1 8

JKN24011

JJoincare Pharmaceutical Group Industry Co., Ltd

Phase 2

1 9

SB17170

SSPARK Biopharma

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phase 21 trial

A Phase 2 Trial of JKN24011 in COPD

Active, not recruiting·JJoincare Pharmaceutical Group Industry Co., Ltd·Phase 2·NCT07440524·215 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JKN24011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JKN24011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JKN24011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Joincare Pharmaceutical Group Industry Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: JJoincare Pharmaceutical Group Industry Co., Ltd

JKN24011

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Phase 21 trial

References

Drug Info

Quick Facts

Related News